The ‘Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors Nordic’ (CVD-REAL Nordic) study, which was sponsored by AstraZeneca, found that patients newly treated with any SGLT2 inhibitor had lower risks of cardiovascular mortality (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.40 to 0.71], major adverse cardiovascular events (HR, 0.78; 95% CI, 0.69 to 0.87) and hospitalisations for heart failure (HR, 0.70; 95% CI, 0.61 to 0.81) compared to patients not initiated on SGLT2 inhibitors14. This evidence concerns the gene SLC5A2 and heart failure.